NC-PERCONA
12.1.2022 11:02:06 CET | Business Wire | Press release
Percona , a leader in open source database software and services, today announced that MultiPay Group, a global payments technology company, has signed with Percona to provide Managed Services for its MySQL open source database deployments.
MultiPay provides a unique, innovative API that acts as a single point of integration between any payment method and any acquirer. MultiPay currently serves a large number of customers in 24 countries including Zara and Frasers Group. The company enables large-scale merchants across retail, hospitality, travel and transportation sectors to accept any payment, anywhere, enabling greater freedom and flexibility for consumers and merchants alike.
However, the company’s service relies on a solid, dependable and available database infrastructure to operate efficiently. MultiPay works with Percona to get the best available advice, expertise and support for its database deployments. MultiPay relies on Percona XtraDB Cluster and Percona Monitoring and Management for its operational database and management.
Delia Pedersoli, Chief Operating Officer at MultiPay said: “Assigning our database management to Percona will enable us to realise greater efficiencies as we continue to grow our technology offering and better serve consumers and merchants with fast, seamless payment experiences. We support global retail customers with their critical payment infrastructure and we plan ahead so that we can always deliver what our customers need. Percona offers that round the clock expert support to help us ensure our databases are running at peak performance, and we can rely on Percona’s unbiased approach as we consider any future deployments too.”
Martin James, Vice President EMEA at Percona said: “The eCommerce marketplace is competitive and customers aren’t willing to put up with poor performance. MultiPay has built a unique offering that revolutionises the payment experience for consumers, and their service must keep up with what they’ve promised. Alongside running Percona XtraDB Cluster for availability, Percona provides 24/7/365 expertise and support to ensure MultiPay’s database performance is aligned with their business goals.”
As part of the agreement, Percona will help provide MultiPay with Managed Services to ensure the necessary high availability of their payment platform as well as the assistance to help them develop their long-term database and cloud strategy. The deal will result in greater cost efficiencies and easier database management for MultiPay, allowing the company to continue its global expansion and support more customers over time. MultiPay’s decision to use Percona Managed Services helps the company take care of its complex technical needs and deliver their mission critical, customer-facing services.
Links
- Percona XtraDB Cluster - https://www.percona.com/software/mysql-database/percona-xtradb-cluster
- Percona Managed Services - https://www.percona.com/services/managed-services/percona-managed-database-services
- Multipay - http://www.multipayglobalsolutions.com
Company Information
About Percona
Databases run better with Percona. Percona is the only company that delivers enterprise-class products, support and services for a range of open source databases including MySQL®, MariaDB®, MongoDB®, and PostgreSQL across traditional deployments, cloud-based platforms and hybrid IT environments. The company is committed to supporting open source as an approach to software licensing, development and deployment - its database management tools are used by millions of application developers, database administrators and IT professionals worldwide.
Percona equips businesses with the freedom to choose, the freedom to create, and the freedom to make a difference — helping them scale with speed as they grow. The company supports global brands such as PayPal, Vimeo, RockStar Games, Duolingo, Fiserv, Slack, Cisco Systems, and Rent the Runway, as well as smaller enterprises looking to maximise application performance while streamlining database efficiencies. For more information, visit www.percona.com .
About MultiPay
Headquartered in London, Milan and now Denmark, MultiPay Global Solutions is a payments technology company that enables large merchants across the world to accept any payment, anywhere. Its all-in-one agnostic payment solution combines a unique API that acts as a single point of integration between any payment method and any acquirer. MultiPay’s gateway works across all payment channels in any sector including retail, hospitality, travel, and transportation. Combined with its personalised, couture experience, MultiPay is the single point of contact for all payment requirements and ensures it delivers payment technology and integration that is built around its customers’ bespoke requirements. For more information about MultiPay Global Solutions, visit www.multipayglobalsolutions.com
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom